
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. demonstrates a promising growth outlook, highlighted by WAKIX's robust revenue performance, which reached $201.3 million in net sales during the fourth quarter of 2024, reflecting a 20% year-over-year increase. The company anticipates a significant upward trajectory in WAKIX sales, projecting growth from approximately $160 million in 2020 to greater than $700 million in 2024, driven by strong adoption among prescribers and a competitive safety profile. Additionally, Harmony's pipeline, including promising drug candidates targeting rare neurological conditions, positions the company to further enhance its growth potential and capitalize on unmet medical needs in the market.
Bears say
Harmony Biosciences Holdings Inc. faces significant challenges affecting its financial outlook, primarily stemming from the potential entry of new competitors in the sodium oxybate market, which could hinder the growth of its primary product, WAKIX. The company has also expressed concerns regarding the potential slowdown in new patient additions for WAKIX, as well as the uncertainty surrounding the success of its ongoing clinical trials for various drug candidates, which are essential for future growth. Additionally, the expectation of earlier-than-anticipated competition from generic pitolisant has compelled the company to adjust its estimated revenues, leading to a $5 reduction in the estimated value of the pitolisant pipeline and a corresponding decrease in the price target from $75 to $70.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares